KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Change in Receivables (2016 - 2025)

AbbVie (ABBV) has disclosed Change in Receivables for 14 consecutive years, with -$162.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 58.14% to -$162.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 billion, a 819.81% increase, with the full-year FY2025 number at $1.5 billion, up 819.81% from a year prior.
  • Change in Receivables was -$162.0 million for Q4 2025 at AbbVie, down from $156.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.5 billion in Q1 2025 to a low of -$590.0 million in Q3 2021.
  • A 5-year average of $199.6 million and a median of $118.0 million in 2023 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 260.0% in 2024; the steepest drop was 17100.0% in 2024.
  • AbbVie's Change in Receivables stood at $749.0 million in 2021, then crashed by 44.46% to $416.0 million in 2022, then tumbled by 181.49% to -$339.0 million in 2023, then fell by 14.16% to -$387.0 million in 2024, then surged by 58.14% to -$162.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Change in Receivables are -$162.0 million (Q4 2025), $156.0 million (Q3 2025), and $17.0 million (Q2 2025).